A PIK3CA-mutant breast cancer metastatic patient-derived organoid approach to evaluate alpelisib treatment for multiple secondary lesions.
Donzelli S, Cioce M, Sacconi A, Zanconato F, Daralioti T, Goeman F, Orlandi G, Di Martino S, Fazio VM, Alessandrini G, Telera S, Carosi M, Ciliberto G, Botti C, Strano S, Piccolo S, Blandino G.
Donzelli S, et al. Among authors: orlandi g.
Mol Cancer. 2022 Jul 22;21(1):152. doi: 10.1186/s12943-022-01617-6.
Mol Cancer. 2022.
PMID: 35869553
Free PMC article.
No abstract available.